1FW2.F WUXI BIOLOGICS-00000083
- Market cap
- EUR 23.1B
- P/E
- 37.3x
- P/B
- 3.58x
- ROE
- 10.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 1FW2.F undervalued?
Graham number1FW2.F trades 143.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
WUXI BIOLOGICS-00000083 fundamental analysis
No fundamental analysis for WUXI BIOLOGICS-00000083 yet.
WUXI BIOLOGICS-00000083 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About WUXI BIOLOGICS-00000083
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, Australia, and Brazil. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstre…
Full company profileWUXI BIOLOGICS-00000083 financial statements
WUXI BIOLOGICS-00000083 annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 10.3B | 15.3B | 17.0B | 18.7B | 21.8B |
| Gross Profit | 4.83B | 6.72B | 6.83B | 7.65B | 10.0B |
| Operating Income | 3.46B | 4.80B | 4.45B | 4.97B | 7.06B |
| EBITDA | - | 6.22B | 5.50B | 6.43B | 8.85B |
| Net Income | 3.39B | 4.42B | 3.40B | 3.36B | 4.91B |
| EPS | 0.80 | 1.05 | 0.80 | 0.82 | 1.19 |
| Balance Sheet | |||||
| Total Assets | 44.0B | 49.6B | 56.6B | 57.0B | 63.7B |
| Total Liabilities | 11.3B | 13.4B | 12.6B | 11.5B | 10.7B |
| Shareholders' Equity | 32.3B | 35.0B | 40.3B | 41.8B | 47.2B |
| Cash & Short-term Investments | 9.00B | 6.40B | 9.67B | 8.28B | 9.21B |
| Cash Flow | |||||
| Operating Cash Flow | 3.43B | 5.54B | 4.67B | 5.22B | 6.34B |
| Capital Expenditure | 6.52B | 5.87B | 4.23B | 3.93B | 3.74B |
| Free Cash Flow | -3.09B | -327M | 437M | 1.29B | 2.61B |
| Ratios | |||||
| ROE | 10.5% | 12.6% | 8.4% | 8.0% | 10.4% |
| ROA | 7.7% | 8.9% | 6.0% | 5.9% | 7.7% |
| Net Profit Margin | 32.9% | 29.0% | 20.0% | 18.0% | 22.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
WUXI BIOLOGICS-00000083 dividends
WUXI BIOLOGICS-00000083 has not paid dividends in the last 5 fiscal years.
Last stock split: 3:1 on Nov 16, 2020.
Who owns WUXI BIOLOGICS-00000083
- Insiders 7.93%
- Institutions 37.06%
- Public & others 55.02%
- Shares outstanding 4.12B
- Free float 3.80B
WUXI BIOLOGICS-00000083 company profile
- Company name
- WUXI BIOLOGICS-00000083
- Ticker
- 1FW2.F
- ISIN
- KYG970081173
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 14,705
- Fiscal year end
- December
- Address
- No. 108, Meiliang Road, Wuxi, China
- Website
- wuxibiologics.com
About WUXI BIOLOGICS-00000083
WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, Australia, and Brazil. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Tumor Associated Antigens ("TAA") mAb Technology, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh. It engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, production and sales of medicals, and biologics clinical and manufacturing services; research and development in relation to biologics; international sales contracting service; vaccine contract development and manufacturing organization (CDMO) and related business; development, production, and distribution of biotechnological products; and engages in investment and material supplier activities. WuXi Biologics (Cayman) Inc. was incorporated in 2014 and is headquartered in Wuxi, China.
WUXI BIOLOGICS-00000083 management
10- Dr. Ge Li Ph.D.Founder & Chairman · born 1967
- Dr. Zhisheng Chen Ph.D.CEO & Executive Director · born 1973
- Dr. Xuejun Gu Ph.D.CTO, Chief Client Officer, EVP of Global Biologics Development Department & Executive Director · born 1971
- Mr. Ming TuCFO & Executive VP · born 1969
- Lihua Yu M.B.A.COO & Senior VP
- Dr. Jijie Gu Ph.D.Chief Scientific Officer & President of Global Biologics Research · born 1966
- Ms. Lina Fan Ph.D.Senior VP & Head of Investor Relations
- Xiaohui Liu M.B.A.Executive VP & Chief Human Resources Officer
- Mr. Jian DongCEO of WuXi Vaccines · born 1964
- Mr. Angus Scott Marshall Turner M.B.A.Senior VP and Head of Global BD & Alliance Management · born 1968